While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibody‒drug conjugates (ADCs) provides a novel alternative. ADCs are a new class of anticancer drugs comprising the coupling of antitumor mAbs with cytotoxic drugs. Compared with chemotherapeutic drugs, ADCs have the advantages of good tolerance, accurate target recognition, and small effects on noncancerous cells. ADCs occupy an increasingly important position in the therapeutic field. Currently, there are 13 Food and Drug Administration (FDA)‒approved ADCs and more than 100 ADC drugs at different stages of clinical trials. This review briefly describes the efficacy and safety of FDA-approved ADCs, and discusses the related problems and challenges to provide a reference for clinical work.

中文翻译：

---

FDA 批准的抗体药物偶联物在人类癌症中的临床疗效综述

尽管化疗和免疫疗法等策略已成为晚期或转移性癌症患者的一线标准疗法，但在大多数情况下获得性耐药仍然是不可避免的。抗体药物偶联物（ADC）的引入提供了一种新的替代方案。 ADC 是一类新型抗癌药物，由抗肿瘤单克隆抗体与细胞毒性药物偶联而成。与化疗药物相比，ADC具有耐受性好、靶点识别准确、对非癌细胞影响小等优点。 ADC在治疗领域占据着越来越重要的地位。目前，已有13个美国食品药品监督管理局（FDA）批准的ADC，以及100多个处于不同临床试验阶段的ADC药物。本综述简要介绍了 FDA 批准的 ADC 的有效性和安全性，并讨论了相关问题和挑战，为临床工作提供参考。